Uncategorized
VIDEO: Novaliq announces full enrollment in phase 2 trial of dry eye treatment
NEW ORLEANS — At the Ophthalmology Innovation Summit, Bernhard Günther, CEO of Novaliq, gives an update on the company portfolio, including news that it had completed enrollment in a phase 2 study of CyclASol for the treatment of moderate to severe dry eye disease.